KEATING LAURIE 4

What Happened

• Laurie Keating, a director of Immuneering Corp (IMRX), received a derivative award on 2026-06-11 covering 33,350 shares. The filing reports the acquisition amount at $0.00 (derivative instrument), and a footnote clarifies these are options that will vest and become exercisable over time.

Key Details

• Transaction date: 2026-06-11; transaction type: Grant/Award (code A).
• Amount: 33,350 shares reported as a derivative award; reported acquisition price: $0.00.
• Vesting/exercise: Vests in equal monthly installments over one year starting July 11, 2026, and will be fully vested and exercisable on June 11, 2027 (or at the 2027 annual meeting, whichever is earlier).
• Exercise price: Not disclosed in the provided excerpt of the filing.
• Shares owned after transaction: Not specified in the provided summary.
• Filing timeliness: Reported for the same date as the transaction (no late-filing indication in provided data).

Context

• This was a grant of a derivative award (option) as director compensation, not an open-market purchase or sale. The options do not become exercisable immediately; they vest monthly beginning July 11, 2026, so there’s a waiting period before Keating can convert them into common shares. Derivative grants are a standard part of executive/director pay and do not by themselves indicate buying or selling sentiment.